Applications published 19 August 2009

Chemokine receptor binding compounds
Genzyme 2088860*

Benzimidazole compounds
Takeda Pharmaceutical 2088861*

Cancer treatment method
SmithKline Beecham 2088862*

Tyrosine kinase inhibitors as antikinetolastid and anti-apicomplexan agents
University of Georgia Research Foundation 2088863*

Selective immunodepletion of endogenous stem cell niche for engraftment
The Board of Trustees of the Leland Sanford Junior University 2088864*

Guggulphospholipid methods and compsns
Jina Pharmaceuticals 2088865*

Liquid pharmaceutical compsn comprising a bisphosphonate
Besins Healthcare 2088996*

Liquid anti-rabies antibody formulations
Crucell Holland 2088997*

Unit dosage package and methods of administering weight loss medications
Orexigen Therapeutics 2088998*

Pharmaceutical compsn comprising an active ingredient which neutralises and/or binds gastric acid, such as an alginic acid derivative
Meria Clementine Matrin Klosterfrau Vertriebsgesellschaft 2088999*

Injectable depot compsn and its process of preparation
Panacea Biotec 2089000*

High protein concentration formulations containing mannitol
Wyeth 2089001*

Phenylalkyl carbamate compsns
Janssen Pharmaceutica 2089002*

Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
Abbott 2089003*

Solid dosage form with a film containing an active substance, as well as its method of production
Abbott 2089004*

Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
Orexigen Therapeutics 2089005*

Medicament with controlled release containing galanthamine
Ratiopharm 2089006*

Transdermal delivery of ketoprofen polar derivatives
Noven Pharmaceuticals 2089007*

Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser
School of Pharmacy, University of London 2089008*

Use of LXR agonists for the treatment of osteoarthritis
Wyeth 2089009*

• Rapid release mini-tablets provide analgesia in laboratory animals
The Johns Hopkins University 2089010*

• Treatment of pervasive developmental disorders
Janssen Pharmaceutica 2089011*

• Polymorphs of N2-(1,1"-biphenyl-4-ylcarbonyl-N1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-L-alpha-glutamine
Wyeth 2089012*

• Acetaminophen/ibuprofen combinations
McNeil-PPC 2089013*

• Omega-3 fatty acids and dyslipidemic agent for reduction of APO-B levels
Reliant Pharmaceuticals 2089014*

• Methods for treating disruptive behaviour disorders
Janssen Pharmaceutica 2089015*

• Method for treating macular degeneration
The Trustees of the University of Pennsylvania 2089016*

• Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
Aestus Therapeutics 2089017*

• Methods of treating cognitive impairment and dementia
Lexicon Pharmaceuticals 2089018*

• Polymorphs of a hydroisoindoline tachykinin receptor antagonist
Merck 2089019*

• Macrocyclic peptides as hepatitis C virus inhibitors
Bristol-Myers Squibb 2089020*

• Use of a carboxyamidotriazole (CAI) orotate in macular degeneration
Tactical Therapies 2089021*

• Compsn containing a mixture of antidepressants for treating premature ejaculation
Medley SA Industrie Farmaceutica 2089022*

• Methods of treating neuropathic pain with agonists of PPAR-gamma
Aestus Therapeutics 2089023*

• Combination of IAP inhibitors and FLT3 inhibitors
Novartis 2089024*

• Thuggacin-type macrolide antibiotics and their use as antimycobacterial agents
Helmholtz-Zentrum fuer Infektionforschung 2089025*

• Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
Novartis 2089026*

• Use of IAP inhibitors for the treatment of acute myeloid leukaemia
Novartis 2089027*

• Method for treating delirium
Avigen 2089028*

• PAK modulators
Massachusetts Institute of Technology 2089029*

• Agent for prophylaxis or treatment of alcohol dependance or drug dependance
Mitsubishi Tanabe Pharma 2089030*

• Reduction of overweight or obesity
N-Gene Research Laboratories 2089031*

• A pharmaceutical compsn having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
N-Gene Research Laboratories 2089032*

• Stroke recovery
CytRx 2089033*

• Novel uses
Intra-Cellular Therapies 2089034*

• Method for treating blepharitis
Riolan Technologies 2089035*

• Method for treating an ocular allergy with low dose dexa-methasone
Riolan Technologies 2089036*

• Mixture and method for reducing cholesterol using hydrophobic microparticles
Ben-Bar Technologies 2089038*

• Method for the production of an agent against an infectious disease
Temper, Rupert 2089043*

• Antiobesity product and its method of preparation
Chongquing Institute of Ecological Materia; Phynova 2089044*

• Use of IL-27 antagonists for the manufacture of a medicament for the treatment of aplastic anaemia
Zymogenetics 2089045*

• Antidiambetogenic calcium-peptide compsn
Humana Milchunion 2089046*

• Compsns and methods for cardiac tissue protection and regeneration
3D Matrix 2089047*

• Compsn for cartilage
The Regents of the University of California 2089048*

• Systemic administration of colony stimulating factors to treat amyloid associated disorders
Biogen Idec 2089049*

• IL-17B for use in wound healing
Zymogenetics 2089050*

• Enhanced immunogenicity of tumour associated antigens by addition of alphagal epitopes
Newlink Genetics; Jaipuri, Firoz 2089051*

• PEG linker compounds and biologically active conjugates thereof
PEG Biosciences 2089052*

• HPV antigen fusion protein vaccine compsns and uses thereof
Sunbio Biotech Pharmaceuticals (Tianjin); Beijing Sunbio Biotech 2089053*

• Novel compsns and uses thereof
Avaris 2089054*

• Method for detecting and controlling cancer
George Mason Intellectual Properties 2089055*

• Biodegradable T-cell activation device and methods
Immunovative Therapies 2089056*

• Methods and compsns for treating and monitoring treatment of IL-13-associated disorders
Wyeth 2089057*

• Methods of treating haemolytic anaemia
Alexion Pharmaceuticals 2089058*

• Method for treating age-related macular degeneration
Genentech 2089059*

• Liquid oreoaration comprising a complex of pimobendan and cyclodextrin
Boehringer Ingelheim 2089060*

• Inhibition of SOX9 function in the treatment of proteoglycan-associated pathophysiological conditions
The University of Western Ontario 2089061*

• Intranasal therapeutics for neuroprotection
Healthpartners Research Foundation 2089062*

• X-ray contrast agent comprising a metal chelate and a polyhalogenated phenol, thiophenol, resorcinol, thioresorcinol or dithioresorcinol
Mallinckrodt 2089063*

• UV treatment reactor
Calgon Carbon 2089064*

• Methods and compsns for prion decontamination
EI du Pont de Nemours 2089065*